5 completed, 5 recruiting, 1 terminated. 11 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Recruiting 5, Terminated 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow molnupiravir: new trials by email Literature Review of molnupiravir trials Research Report on molnupiravir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| Assessing Antiviral Treatments in Early Symptomatic RSV Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human | Phase 2 | Recruiting | University of Oxford | 1000 | 2024-07-25 | 2025-07-02 |
| A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human | Phase 2 | Recruiting | University of Oxford | 3000 | 2023-02-22 | 2026-04-14 |
| Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Molnupiravir, Placebo, RSV A Memphis 37b - Respiratory Syncytial Virus | Phase 2 | Completed | Merck Sharp & Dohme LLC | 116 | 2022-11-02 | 2025-07-18 |
| A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa Molnupiravir 200 mg - COVID-19 | Phase 2 / Phase 3 | Completed | University of Witwatersrand, South Africa | 59 | 2022-08-12 | 2025-07-01 |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | University of Oxford | 3800 | 2021-09-30 | 2026-02-19 |
| Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) Molnupiravir, Placebo - Coronavirus Disease (COVID-19) | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 304 | 2020-10-19 | 2023-01-17 |
| Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) Molnupiravir, Placebo - Coronavirus Disease (COVID-19) | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 1735 | 2020-10-19 | 2023-06-28 |
| AGILE (Early Phase Platform Trial for COVID-19) CST-2: EIDD-2801, CST-2: Placebo, Nitazoxanide - Covid19 | Phase 1 / Phase 2 | Recruiting | University of Liverpool | 600 | 2020-07-03 | 2026-06-01 |
| Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Completed | Ridgeback Biotherapeutics, LP | 204 | 2020-06-19 | 2022-02-16 |
| The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) EIDD-2801, Placebo - SARS-CoV 2 | Phase 2 | Completed | Ridgeback Biotherapeutics, LP | 71 | 2020-06-16 | 2023-03-23 |
COVID-19 (6) · Dengue (1) · Influenza, Human (1)
Merck Sharp & Dohme LLC (3) · University of Oxford (3) · Ridgeback Biotherapeutics, LP (2) · Oxford University Clinical Research Unit, Vietnam (1) · University of Liverpool (1) · University of Witwatersrand, South Africa (1)
Brazil (4) · South Africa (4) · United Kingdom (4) · United States (4) · Laos (3) · Thailand (3) · Canada (2) · Chile (2) · Colombia (2) · France (2) · Israel (2) · Italy (2) · Mexico (2) · Nepal (2) · Philippines (2)
Ashwin Balagopal, MD (1) · Francois WD Venter (1) · Saye Khoo (1) · Sophie Yacoub, MD., PhD. (1)
PMID 33273742, PMID 34100024, PMID 34159342, PMID 34450619, PMID 34473343, PMID 34699618, PMID 34914868, PMID 35022711, PMID 35271729, PMID 35667065, PMID 36272432, PMID 36435798, PMID 36648627, PMID 36803992, PMID 37017631, PMID 37466374, PMID 37470445, PMID 37778363, PMID 37995070, PMID 38225598, PMID 38319178, PMID 38319179, PMID 38677300, PMID 39896880, PMID 40025641, PMID 40175624, PMID 41082886, PMID 41125063, PMID 41321979, PMID 41848748, PMID 42520824